A randomized, two-way crossover study to investigate the bioavailability of a single oral dose of 12.5 mg carbidopa, 50 mg levodopa and 200 mg entacapone compared to a single oral combined dose of both 12.5 mg carbidopa and 50 mg levodopa and 200 mg entacapone in healthy volunteers under fed conditions

Trial Profile

A randomized, two-way crossover study to investigate the bioavailability of a single oral dose of 12.5 mg carbidopa, 50 mg levodopa and 200 mg entacapone compared to a single oral combined dose of both 12.5 mg carbidopa and 50 mg levodopa and 200 mg entacapone in healthy volunteers under fed conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2007

At a glance

  • Drugs Entacapone; Levodopa/carbidopa; Levodopa/carbidopa/entacapone
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 30 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top